Alumis’ (ALMS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Alumis (NASDAQ:ALMS) in a report released on Monday morning,Benzinga reports. They currently have a $19.00 target price on the stock.

Other equities analysts also recently issued research reports about the company. Oppenheimer assumed coverage on Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Alumis currently has a consensus rating of “Buy” and an average target price of $26.57.

Alumis Trading Up 2.8 %

Shares of ALMS opened at $4.72 on Monday. The stock has a fifty day moving average price of $6.52 and a two-hundred day moving average price of $9.26. Alumis has a 52-week low of $4.36 and a 52-week high of $13.53.

Institutional Investors Weigh In On Alumis

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Foresite Capital Management VI LLC acquired a new stake in shares of Alumis during the fourth quarter worth $33,033,000. Samsara BioCapital LLC acquired a new stake in shares of Alumis during the third quarter worth $34,886,000. Geode Capital Management LLC acquired a new stake in shares of Alumis during the third quarter worth $3,266,000. Norges Bank acquired a new stake in shares of Alumis during the fourth quarter worth $1,606,000. Finally, Foresite Capital Management V LLC grew its stake in shares of Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after purchasing an additional 194,459 shares during the period.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.